Clinical Trial Update: Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the safety of switching Hemophilia A patients to ReFacto AF in usual care; the trial was terminated with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refacto AF (Factor VIII, recombinant)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Phase 4 | Status: TERMINATED | Results posted: 2014-09-01